EGFR and non-small cell lung carcinoma: The NCCN (2019, v3) recommended that testing for EGFR mutations should be applied in patients with non-squamous NSCLC or NSCLC NOS (not otherwise specified) so that patients with this genetic abnormality can receive effective treatment with targeted agents.